Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | ULK1 | O75385 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | MPL | P40238 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | SGK1 | O00141 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30791233 | 1.00 | EGFR (0.43) | EGFRKDRULK1RIPK1AR | |
| SCHEMBL30791247 | 0.88 | EGFR (0.35) | EGFRKDRULK1EPHX2PIK3CA | |
| SCHEMBL23369587 | 0.88 | DHODH (0.42) | EGFRKDRULK1PIK3CAPIK3CB | |
| SCHEMBL23356058 | 0.88 | EGFR (0.35) | EGFRKDRULK1EPHX2PIK3CA | |
| SCHEMBL30791216 | 0.85 | SGK1 (0.33) | KDRSGK1 | |
| SCHEMBL23356099 | 0.85 | SGK1 (0.33) | KDRSGK1 | |
| SCHEMBL30791280 | 0.84 | TRPA1 (0.34) | EGFRKDRULK1SGK1PIK3CA | |
| SCHEMBL23356081 | 0.84 | TRPA1 (0.34) | EGFRKDRULK1SGK1PIK3CA | |
| SCHEMBL23356027 | 0.83 | GRM4 (0.47) | EGFRKDRSGK1 | |
| SCHEMBL30791242 | 0.83 | GRM4 (0.47) | EGFRKDRSGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583852-B2 | Heterocycle derivative | JW PHARMACEUTICAL CORPORATION (KR) | 2026-03-24 | — | — | US | disclosed |
| CN-112313232-B | Novel heterocyclic derivatives | JW中外制药公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20220259199-A1 | NOVEL HETEROCYCLE DERIVATIVE | JW PHARMACEUTICAL CORPORATION (KR) | 2022-08-18 | — | — | US | disclosed |
| EP-3822270-A1 | NOVEL HETEROCYCLE DERIVATIVE | JW Pharmaceutical Corporation (KR) | 2021-05-19 | — | — | EP | disclosed |
| CN-112313232-A | Novel heterocyclic derivatives | JW中外制药公司 | 2021-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583852-B2 | Heterocycle derivative | AR, SRD5A1, NR5A1 | EGFR 787/4885KDR 4174/4885ULK1 3625/4885 |
| US-20220259199-A1 | NOVEL HETEROCYCLE DERIVATIVE | AR, BRDT, NR5A1 | EGFR 1730/4885KDR 4122/4885ULK1 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.